LOGIN  |  REGISTER
Assertio

Stryker announces Annual Meeting of Shareholders

March 26, 2024 | Last Trade: US$354.09 1.12 0.32

Portage, Michigan, March 26, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2024 Annual Meeting of Shareholders is scheduled as follows:

Thursday, May 9, 2024 – 9:30 a.m. Eastern Time

The Meeting will be held virtually via the internet. Information about the webcast, which will include both the audio and the slide presentation from the meeting, is available on the Investor Relations page of our website at www.investorevents.stryker.com. To listen to the meeting as a guest dial (877) 328-2502 (U.S.) or (412) 317-5419 (International) and request the "Stryker Corporation Annual Meeting" when greeted by the operator.

A recording of the annual meeting will also be available from 10:30 a.m., Eastern Time, on Friday, May 10, 2024 at www.virtualshareholdermeeting.com/SYK2024 until the definitive proxy statement for our 2025 Annual Meeting of Shareholders is filed with the United States Securities and Exchange Commission.

About Stryker

Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it. 

For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page